FDA Oncology Announcements

Megakaryocyte growth factor × Clear all

7 Announcements

FDA approves romiplostim for pediatric patients with immune thrombocytopenia

Drug: NPLATE (romiplostim) · Megakaryocyte growth factor
Condition: Classical hematology

FDA approves lusutrombopag for thrombocytopenia in adults with chronic liver disease

Trial: L-PLUS 2
Drug: Mulpleta (lusutrombopag) · Megakaryocyte growth factor
Condition: Classical hematology

FDA approves avatrombopag for thrombocytopenia in adults with chronic liver disease

Drug: Doptelet (avatrombopag) · Megakaryocyte growth factor
Condition: Classical hematology

Eltrombopag / Promacta

Drug: Promacta for oral suspension (eltrombopag) · Megakaryocyte growth factor
Condition: Classical hematology

Romiplostim/Eltrombopag

Drugs: Nplate for subcutaneous (romiplostim) · Megakaryocyte growth factor, Promacta tablets (eltrombopag) · Megakaryocyte growth factor
Condition: Classical hematology

Eltrombopag

Drug: Promacta (eltrombopag) · Megakaryocyte growth factor
Condition: Classical hematology

FDA Approves Romiplostim

Drugs: Nplate (romiplostim for subcutaneous) · Megakaryocyte growth factor, Nplate (subcutaneous)
Condition: Classical hematology